I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Date) |
| | |||
DOV |
Merck & Co. Inc. |
They amended 2004 deal covering clinical development of DOV 21,947 and DOV 216,303, following early trial data on 21,947 |
Certain early stage clinical trials for DOV 21,947 now will be undertaken by DOV; DOV would be reimbursed if Phase II results of the depression candidate are successful (8/8) |
Karo Bio AB |
Wyeth Pharmaceuticals |
They extended a deal signed in 2001 for an additional year |
They are working on new treatments for atherosclerosis by targeting the liver X receptor; terms were not disclosed (8/15) |
Memory |
Hoffmann-La Roche Inc. |
Memory reacquired the rights to the PDE4 inhibitors MEM 1414 and MEM 1917, which Roche stopped developing for Alzheimer's disease in April |
Roche has an option to continue development of the drugs after Phase II trials; Roche also maintains exclusive rights to all other drug candidates from Memory's PDE4 inhibitor program (8/18) |
Qiagen Nv |
Abbott Laboratories |
Abbott got distribution rights to a number of PCR diagnostic tests under an extension to an existing deal |
Abbott has nonexclusive distribution rights to certain Qiagen products; the PCR assays were developed by Artus GmbH, which Qiagen acquired (6/22) |
Senetek plc |
Valeant Pharmaceuticals International |
Valeant got expanded distribution rights for Kinetin and exclusive worldwide rights to Zeatin |
Senetek will get minimum royalty payments of $37M through 2010 for the skincare product Kinetin (Kinerase), plus potential additional royalties (8/9) |
Gilead |
Hoffmann-La Roche Inc. |
Gilead is seeking to terminate a 1996 agreement on the influenza product Tamiflu |
Gilead is alleging material breach of the agreement, and wants to regain all rights to the product held by Roche (6/23) |
II. TERMINATED AGREEMENTS | |||
Advancis |
Par Pharmaceutical Corp. |
Par terminated a deal covering Advancis' Amoxicillin Pulsys product |
The move followed a failed trial in strep throat; Par may be entitled to a portion of some future revenues (8/4) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange. | |||
